Description

Piflufolastat F 18 is a diagnostic radiopharmaceutical agent used in positron emission tomography (PET) imaging. Its core value lies in targeting prostate-specific membrane antigen (PSMA), enabling the highly sensitive and specific detection of prostate cancer lesions. This product is essential for nuclear medicine departments, oncology research centers, and pharmaceutical companies involved in diagnostic imaging and the development of targeted cancer therapies. Piflufolastat F 18 CAS NO 1207181-29-0 represents a critical tool for improving patient staging and treatment monitoring.

Application

• PET Imaging for Prostate Cancer: Primary use for the detection and localization of prostate cancer, including primary tumors and metastatic sites.
• Biochemical Recurrence Staging: Evaluation of patients with rising prostate-specific antigen (PSA) levels after initial treatment to identify site of recurrence.
• Treatment Planning and Monitoring: Assisting in treatment decision-making and assessing response to therapy, including radiotherapy and systemic treatments.
• Clinical Research: Utilization as a tracer in clinical trials for novel prostate cancer therapeutics and diagnostic protocols.
• Radiopharmaceutical Manufacturing: Serves as the active pharmaceutical ingredient (API) or precursor in the GMP production of finished dose formulations.
• Academic Research: Used in preclinical and translational studies to investigate PSMA biology and develop next-generation imaging agents.

Basic Information

Product Name	Piflufolastat F 18
CAS No.	1207181-29-0
Molecular Formula	C39H47F3N6O7
Molecular Weight	768.83 g/mol
Synonyms	18F-DCFPyL; DCFPyL (18F); Piflufolastat (18F); [18F]DCFPyL; (2R,4S)-4-(((S)-1-((S)-4-Carboxy-2-((6-(3-[(18)F]fluoropropyl)pyridin-3-yl)carbamoyl)pyrrolidin-1-yl)-3-(4-fluorophenyl)-1-oxopropan-2-yl)carbamoyl)-7-fluoro-2,3-dihydro-1H-indene-2-carboxylic acid; Pylarify® (branded finished product); PSMA-1007 (related research compound); Fluorine-18 labeled PSMA inhibitor.
EINECS	Contact for details

Quality Control

Our Piflufolastat F 18 is manufactured and controlled under a strict quality management system. Production adheres to current Good Manufacturing Practice (cGMP) guidelines suitable for radiopharmaceutical applications. Each batch is released based on comprehensive analytical testing, including radiochemical purity, chemical purity, specific activity, radionuclidic identity, pH, sterility, and bacterial endotoxins. A comprehensive Certificate of Analysis (COA) detailing all release specifications is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature or as specified on the label. Due to the radioactive nature of Fluorine-18, all handling and storage must comply with local radiation safety regulations. The product must be used within its validated shelf-life post-calibration.

Specification

Item	Specification
Appearance	Clear, colorless solution
Identification (HPLC)	Conforms to reference standard
Radiochemical Purity (HPLC)	≥ 95%
Chemical Purity (HPLC)	≥ 99.0%
Specific Activity	Contact for details
Radionuclidic Identity (Half-life)	109.8 ± 2 min
pH	4.5 - 7.5
Sterility	Sterile
Bacterial Endotoxins	< 175 EU/V

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.